Terms: = Lymphoma AND NRG1, ENSG00000157168, 3084, SMDF, NDF, HRGA, HRG1, HGL, GGF2, GGF, ARIA
25 results:
1. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.
Xiao L; Liu Y; Chen H; Shen L
Cancer Biol Ther; 2023 Dec; 24(1):2219470. PubMed ID: 37272701
[TBL] [Abstract] [Full Text] [Related]
2. Silicone Breast Implant Surface Texture Impacts Gene Expression in Periprosthetic Fibrous Capsules.
Daneshgaran G; Gardner DJ; Chen HA; Niknam-Bienia S; Soundararajan V; Raghuram AC; Kim GH; Labaj P; Kreil DP; Wang C; Hong YK; Wong AK
Plast Reconstr Surg; 2023 Jan; 151(1):85-95. PubMed ID: 36205692
[TBL] [Abstract] [Full Text] [Related]
3. Pan-HER inhibitors overcome lorlatinib resistance caused by nrg1/HER3 activation in ALK-rearranged lung cancer.
Taniguchi H; Akagi K; Dotsu Y; Yamada T; Ono S; Imamura E; Gyotoku H; Takemoto S; Yamaguchi H; Sen T; Yano S; Mukae H
Cancer Sci; 2023 Jan; 114(1):164-173. PubMed ID: 36086904
[TBL] [Abstract] [Full Text] [Related]
4. First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.
Diamond JR; Boni V; Lim E; Nowakowski G; Cordoba R; Morillo D; Valencia R; Genvresse I; Merz C; Boix O; Frigault MM; Greer JM; Hamdy AM; Huang X; Izumi R; Wong H; Moreno V
Clin Cancer Res; 2022 Apr; 28(7):1285-1293. PubMed ID: 35046056
[TBL] [Abstract] [Full Text] [Related]
5. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
[TBL] [Abstract] [Full Text] [Related]
6. Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia.
Larsen RH; Hjalgrim LL; Degn M; Nersting J; Als-Nielsen B; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Jul; 88(1):53-60. PubMed ID: 33754188
[TBL] [Abstract] [Full Text] [Related]
7. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.
Tan AC; Itchins M; Khasraw M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103
[TBL] [Abstract] [Full Text] [Related]
8. Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission.
Hawkes EA; Loh Z; Estacio O; Chong G; Ha FJ; Gilbertson M; Grigg A
Br J Cancer; 2018 Aug; 119(5):546-550. PubMed ID: 30033446
[TBL] [Abstract] [Full Text] [Related]
9. Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin lymphoma.
Hijazi Y; Klinger M; Kratzer A; Wu B; Baeuerle PA; Kufer P; Wolf A; Nagorsen D; Zhu M
Curr Clin Pharmacol; 2018; 13(1):55-64. PubMed ID: 29773068
[TBL] [Abstract] [Full Text] [Related]
10. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
11. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract] [Full Text] [Related]
12. Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.
Amengual JE; Prabhu SA; Lombardo M; Zullo K; Johannet PM; Gonzalez Y; Scotto L; Serrano XJ; Wei Y; Duong J; Nandakumar R; Cremers S; Verma A; Elemento O; O'Connor OA
Clin Cancer Res; 2017 Jun; 23(12):3084-3096. PubMed ID: 27993968
[No Abstract] [Full Text] [Related]
13. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
Dong X; Fernandez-Salas E; Li E; Wang S
Neoplasia; 2016 Mar; 18(3):162-71. PubMed ID: 26992917
[TBL] [Abstract] [Full Text] [Related]
14. Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
Sunami K; Furuta K; Tsuta K; Sasada S; Izumo T; Nakaoku T; Shimada Y; Saito M; Nokihara H; Watanabe S; Ohe Y; Kohno T
J Thorac Oncol; 2016 Feb; 11(2):203-12. PubMed ID: 26845116
[TBL] [Abstract] [Full Text] [Related]
15. Residential exposure to traffic noise and risk for non-hodgkin lymphoma among adults.
Sørensen M; Harbo Poulsen A; Ketzel M; Oksbjerg Dalton S; Friis S; Raaschou-Nielsen O
Environ Res; 2015 Oct; 142():61-5. PubMed ID: 26113038
[TBL] [Abstract] [Full Text] [Related]
16. Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-nrg1 translocation case.
Gow CH; Wu SG; Chang YL; Shih JY
Med Oncol; 2014 Jul; 31(7):34. PubMed ID: 24913807
[TBL] [Abstract] [Full Text] [Related]
17. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
Mainwaring PN; Cunningham D; Gregory W; Hoskin P; Hancock B; Norton AJ; MacLennan K; Smith P; Hudson GV; Linch D
Blood; 2001 May; 97(10):2991-7. PubMed ID: 11342422
[TBL] [Abstract] [Full Text] [Related]
18. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma.
Kamath SS; Marcus RB; Lynch JW; Mendenhall NP
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):563-8. PubMed ID: 10348285
[TBL] [Abstract] [Full Text] [Related]
19. A comparison of three methods of analysis for age-period-cohort models with application to incidence data on non-Hodgkin's lymphoma.
McNally RJ; Alexander FE; Staines A; Cartwright RA
Int J Epidemiol; 1997 Feb; 26(1):32-46. PubMed ID: 9126501
[TBL] [Abstract] [Full Text] [Related]
20. Localization of the human HER4/erbB-4 gene to chromosome 2.
Zimonjic DB; Alimandi M; Miki T; Popescu NC; Kraus MH
Oncogene; 1995 Mar; 10(6):1235-7. PubMed ID: 7700649
[TBL] [Abstract] [Full Text] [Related]
[Next]
